SCOPUS 정보 검색 플랫폼

Journal of Oncology Practice

Volumn 8, Issue 4, 2012, Pages 231-232

What patients and providers should understand about economic evaluations in oncology

(2) De Souza, Jonas A a De Lima Lopes, Gilberto b

a UNIVERSITY OF CHICAGO MEDICAL CENTER (United States)

b Johns Hopkins Singapore (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA BASE; DRUG DESIGN; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFORMATION DISSEMINATION; NEOPLASM; NOTE; ONCOLOGY; PATIENT EDUCATION; PHYSICIAN; PRODUCTIVITY;

EID: 84870349598 PISSN: 15547477 EISSN: 1935469X Source Type: Journal
DOI: 10.1200/JOP.2012.000612 Document Type: Note

Times cited : (3)

References (9)

1
- 0041435762
- American Cancer Society: Cancer facts and figures 2011. www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771. pdf
- (2011) Cancer Facts and Figures

2
- 0031886073
- An introduction to Markov modelling for economic evaluation
- DOI 10.2165/00019053-199813040-00003
- Briggs A, Sculpher M: An introduction to Markov modelling for economic evaluation. PharmacoEconomics 13:397-409, 1998 (Pubitemid 28140699)
- (1998) PharmacoEconomics , vol.13 , Issue.4 , pp. 397-409
- Briggs, A.¹ Sculpher, M.²

3
- 0021615244
- Economic analysis and clinical trials
- Drummond MF, Stoddart GL: Economic analysis and clinical trials. Contr Clin Trials 5:115-128, 1984 (Pubitemid 14025836)
- (1984) Controlled Clinical Trials , vol.5 , Issue.2 , pp. 115-128
- Drummond, M.F.¹ Stoddart, G.L.²

4
- 27744468588
- Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report
- DOI 10.1111/j.1524-4733.2005.00045.x
- Ramsey S, Willke R, Briggs A, et al: Good research practices for costeffectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health 8:521-33, 2005 (Pubitemid 41727304)
- (2005) Value in Health , vol.8 , Issue.5 , pp. 521-533
- Ramsey, S.¹ Willke, R.² Briggs, A.³ Brown, R.⁴ Buxton, M.⁵ Chawla, A.⁶ Cook, J.⁷ Glick, H.⁸ Liljas, B.⁹ Petitti, D.¹⁰ Reed, S.¹¹

5
- 0003458828
- (ed 3). London, United Kingdom, Oxford Medical Publications
- Drummond MF, Sculpher MJ, Torrance GW, et al: Methods for the Economic Evaluation of Health Care Programmes (ed 3). London, United Kingdom, Oxford Medical Publications, 2005
- (2005) Methods for the Economic Evaluation of Health Care Programmes
- Drummond, M.F.¹ Sculpher, M.J.² Torrance, G.W.³

6
- 0027489581
- Cost-benefit-analysis. 5
- Robinson, R: Cost-benefit-analysis. 5. BMJ 307:924-926, 1993
- (1993) BMJ , vol.307 , pp. 924-926
- Robinson, R.¹

7
- 84870352045
- Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease. Could cost weigh in evaluation?
- doi: 10.1200/JOP.2011.000390
- Guirgis HM: Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease. Could cost weigh in evaluation? J Oncol Pract doi: 10.1200/JOP.2011.000390
- J Oncol Pract
- Guirgis, H.M.¹

8
- 77954499870
- NICE rejects drug for metastatic breast cancer because of cost and poor efficacy
- Pownall M: NICE rejects drug for metastatic breast cancer because of cost and poor efficacy. BMJ 340:c3145, 2010
- (2010) BMJ , vol.340
- Pownall, M.¹

9
- 45549088555
- Information on cost-effectiveness: An essential product of a national comparative effectiveness program
- American College of Physicians
- American College of Physicians: Information on cost-effectiveness: An essential product of a national comparative effectiveness program. Ann Intern Med 148:956-961, 2008
- (2008) Ann Intern Med , vol.148 , pp. 956-961

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.